RxDoctor Payments Data

Maria Garcia-Ayala

Neurology · San Juan, PRNPI 1518369925

Payments from drug & device makers

What this record shows

20 manufacturers reported payments, led by AbbVie at 48.7% of the total. 2025 is the largest year on record at $4,274, more than ten times the $309 reported in 2019.

$10,374in general payments, 2019–2025

Across 112 payments — averaging $92.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Pfizer$2K
  • PBG Puerto Rico LLC$586
  • EMD Serono, Inc.$567
  • Teva Pharmaceuticals USA, Inc.$442
  • Lundbeck LLC$320
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$5,75055%
  • Food & beverage$4,62445%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,374 in reported general payments places this provider in the 85th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,086
Medicare patients
30
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm375$272,668
Nurtec OdtRimegepant Sulfate205$226,157
UbrelvyUbrogepant148$223,837
Aimovig AutoinjectorErenumab-Aooe72$55,985
Emgality SyringeGalcanezumab-Gnlm54$43,615
QuliptaAtogepant27$29,654
BotoxOnabotulinumtoxina13$16,272
Ajovy AutoinjectorFremanezumab-Vfrm21$14,914
Ondansetron Hcl461$6,075
Eletriptan HbrEletriptan Hydrobromide72$4,796
Gabapentin339$4,357
Baclofen540$3,958
Divalproex Sodium ErDivalproex Sodium169$3,857
RizatriptanRizatriptan Benzoate217$3,706
Nortriptyline Hcl321$3,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$5,056$269,763188 claims
PfizerNurtec Odt$1,615$226,157205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →